by Hunter Moody
ESMO will once again showcase the latest groundbreaking therapies and clinical advancements within the oncology space. At Kognitic, we analyzed all of this year’s abstracts to identify the key highlights. Here we present our takeaways and analytics for the upcoming ESMO 2023 conference.
Immuno-oncology, targeted therapies (particularly small molecule inhibitors), and antibody-drug conjugates (ADCs) continue to be a major focus: Notably, many trials are combining targeted therapy with IO agents.
Key Targets at ESMO
Increased interest in predictive biomarkers and genomic profiling: There is significant interest in selecting patients who will most likely benefit from certain therapies. Top biomarkers associated with trials to be presented at ESMO 2023 include HER2, EGFR, PD-L1, ALK, BRAF, HR, ROS1, BRCA, MSI-H, and PD-1. Notably, ctDNA and other liquid biopsy approaches are being evaluated as well.
Novel radiopharmaceuticals and radionuclide therapies: Several agents are being actively evaluated in various tumor types, such as prostate, breast, head and neck, and neuroendocrine tumors. The radioligand sector’s momentum continues, with the recent acquisition of Point Biopharma by Eli Lilly. Anticipation is building for significant developments, especially in the context of key prostate cancer trials
Neoadjuvant and adjuvant therapies continue to be important: Evaluating therapies earlier in the disease course is an area of focus with the goal of improving outcomes. Many (neo)adjuvant trials are in phase 2/3, as seen in the breakdown below.
Health-related quality of life and patient-reported outcomes are being evaluated
in many trials, underscoring their importance.
ESMO 2023 Showcases Trials Predominantly in NSCLC, BC, and CRC: Trials that include non-small cell lung cancer (NSCLC), breast cancer (BC), and/or colorectal cancer (CRC) make up nearly half of the 493 total interventional trials at ESMO 2023.
Early-phase development leads the way: : Looking at interventional trials, 99 (20%) are Phase 1, 292(59%) are Phase 2, and 102 (21%) are Phase 3 trials.
For more insights, check out Kognitic’s open-access ESMO 2023 dashboard
Learn more at www.kognitic.com
Copyright© 2023 Kognitic, inc. All rights reserved.*
Comments are closed.